Last reviewed · How we verify
Palbociclib 125mg — Competitive Intelligence Brief
phase 2
Live · refreshed every 30 min
Target snapshot
Palbociclib 125mg (palbociclib-125mg) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Palbociclib 125mg TARGET | palbociclib-125mg | Pfizer Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Palbociclib 125mg CI watch — RSS
- Palbociclib 125mg CI watch — Atom
- Palbociclib 125mg CI watch — JSON
- Palbociclib 125mg alone — RSS
Cite this brief
Drug Landscape (2026). Palbociclib 125mg — Competitive Intelligence Brief. https://druglandscape.com/ci/palbociclib-125mg. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab